New research out of the University of Pittsburgh underscores the importance of using male and female subjects in studies.
Pitt researchers studying the body’s response to physical trauma, as from a major car accident or traumatic brain injury, discovered the alcohol abuse medication disulfiram could successfully be used to stop cell death in a medical trauma model using mice. That response was stronger in female mice, with them faring better after the treatment than the males. Researchers saw the same sex pattern when examining existing human data.
The results show not only that disulfiram could be a key treatment for tissue trauma and shock, but also highlight the importance of carrying out experiments in both sexes, something science has slacked on in the past. The study was published May 28 in the journal Science Translational Medicine.
Timothy Billiar, senior author on the disulfiram paper and executive vice president and chief scientific officer for UPMC, and his team used an equal number of female and male mice in their study.
“We take to heart very much the importance of studying this in both sexes,” said Billiar, who’s also chair of surgery at Pitt’s School of Medicine. “It’s not always done for many reasons. Sometimes there’s a good reason to use one sex or another, because it’s a disease that occurs predominantly in one sex or another. But a lot of times, it’s done simply out of convenience.”
Women and minorities were only required to be included in clinical research by the National Institutes of Health starting in 1993. Using mice for research increased in the first half of the 20th century and became a dominant model for animal research involving genetics around the 1980s, but the study of male mice has for decades eclipsed that of female mice.
Between 60% and 80% of scientific studies using animal models in the first half of the 20th century failed to report the sex breakdown of subjects, UC Berkeley neuroscientists Irving Zucker, Brian Prendergast and Annaliese Beery noted in a 2022 article. And a 2011 analysis, also by Zucker and Beery, found there were nearly six times more studies of male mice in neuroscience research than there were female mice. Researchers have argued this has led to a lack of knowledge about female biology and women’s health, as well as the misdiagnosis of mental illness in women, such as anxiety disorders.
Heart attacks, stroke and ADHD have been misdiagnosed in women because symptom profiles are based on the male experience, argue two neuroscientists in a 2021 Nature Neuroscience article.
In science, the decision to stick to studying male mice is often justified because of the female hormonal cycle that has been thought to interfere with study results.
The Pitt study looked at a key pathway for inflammation and cell death associated with tissue trauma to examine the potential for new treatments.
Trauma from unintentional accidents is the third leading cause of death in U.S. adults, per the Centers for Disease Control and Prevention, and there are few treatments to help a person recover.
When the body experiences a medical emergency like blunt force trauma, a variety of chemical cascades are set off to help with wound healing and repair.
Multiple destructive processes are also kicked off. One cell death response, called pyroptosis, where cells essentially explode (think “pyro” or fire), often leads to systemic inflammation and worse outcomes for patients.
The researchers discovered that pyroptosis was a key pathway for cell death and systemic inflammation in the mice experiencing tissue trauma and shock, and that this pathway was more active in female mice compared to males. That process was facilitated by a protein called gasdermin D, largely thought to play a role in trauma and shock.
When researchers gave the mice disulfiram, the female mice responded more strongly than the male mice. The same pattern was observed in mice who had the gasdermin D gene deleted by scientists.
“The difference between males and females is striking,” said Billiar in a May news release about the study. “This could mean that, in a precision medicine approach to trauma, we give gasdermin D inhibitors to women and a different drug or combination of drugs to men.”
Their next step in the research is to move up the ladder with a more complex animal model, with the ultimate goal of human clinical trials.
“We’re really exploring how we can try to treat humans in a clinical trial setting with inhibitors of this pathway,” said Billiar, referring to the pyroptosis pathway.
But, he noted, they can’t do that without funding and support for their research. The study was supported by grants from the National Institutes of Health — specifically the National Heart, Lung & Blood Institute — totaling nearly $5 million.
They hope the present research can continue as planned.
“We can’t do this kind of work without funding from the National Institutes of Health or Department of Defense, the traditional sources of funding,” he said. “And there are no good targeted therapies in trauma to try to reduce these overactivation pathways and save lives.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.